|
|
Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >
Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis : results of the GO-FORTH study
This item is licensed under:Creative Commons Attribution-NonCommercial 3.0 Unported
| Title: | Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis : results of the GO-FORTH study |
| Authors: | Tanaka, Yoshiya Browse this author →KAKEN DB | | Harigai, Masayoshi Browse this author →KAKEN DB | | Takeuchi, Tsutomu Browse this author →KAKEN DB | | Yamanaka, Hisashi Browse this author →KAKEN DB | | Ishiguro, Naoki Browse this author →KAKEN DB | | Yamamoto, Kazuhiko Browse this author →KAKEN DB | | Miyasaka, Nobuyuki Browse this author →KAKEN DB | | Koike, Takao Browse this author →KAKEN DB | | Kanazawa, Minoru Browse this author →KAKEN DB | | Oba, Takuya Browse this author | | Yoshinari, Toru Browse this author | | Baker, Daniel Browse this author | | The GO-FORTH Study Group Browse this author |
| Issue Date: | Jun-2012 |
| Publisher: | BMJ Publishing Group |
| Journal Title: | Annals of the Rheumatic Diseases |
| Volume: | 71 |
| Issue: | 6 |
| Start Page: | 817 |
| End Page: | 824 |
| Publisher DOI: | 10.1136/ard.2011.200317 |
| Abstract: | Objective: To assess the efficacy and safety of golimumab + methotrexate (MTX) in Japanese patients with active rheumatoid arthritis (RA). Methods: 269 Japanese patients with active RA despite treatment with MTX were randomised (1:1:1) to placebo + MTX (Group 1), golimumab 50 mg + MTX (Group 2) or golimumab 100 mg + MTX (Group 3). Subcutaneous golimumab/placebo was injected every 4 weeks; stable doses of oral MTX (6-8 mg/week) were continued. Patients were allowed to enter early escape (Group 1 added golimumab 50 mg, Group 2 increased golimumab to 100 mg, Group 3 continued golimumab 100 mg) based on swollen/tender joint counts at week 14. The primary study endpoint was achievement of at least 20% improvement in the American College of Rheumatology (ACR20) response criteria at week 14. To control for multiplicity of testing, treatment group comparisons were first made between combined Groups 2 and 3 versus Group 1, followed by comparisons of Group 2 and Group 3 versus Group 1. Results: The proportion of patients with an ACR20 response at week 14 was significantly higher in combined Groups 2 and 3 (73.4%, 127/173) and in each of Group 2 (72.1%, 62/86) and Group 3 (74.7%, 65/87) compared with Group 1 (27.3%, 24/88; p<0.0001 for all comparisons). Golimumab + MTX also elicited a significantly better response than placebo + MTX in other efficacy parameters, including disease activity score (DAS28) response/remission and radiographic assessments. During the 16-week fixed treatment regimen study period, 72.7%, 75.6% and 78.2% of patients had adverse events and 1.1%, 1.2% and 2.3% had serious adverse events in Groups 1, 2 and 3, respectively. Conclusion: In Japanese patients with active RA despite MTX therapy, golimumab + MTX was significantly more effective than MTX monotherapy in reducing RA signs/symptoms and limiting radiographic progression with no unexpected safety concerns. |
| Rights: | This article has been accepted for publication in Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study, Yoshiya Tanaka, Masayoshi Harigai, Tsutomu Takeuchi, Hisashi Yamanaka, Naoki Ishiguro, Kazuhiko Yamamoto, Nobuyuki Miyasaka, Takao Koike, Minoru Kanazawa, Takuya Oba, Toru Yoshinari and Daniel Baker, Ann Rheum Dis, 2012, 71(6), pp.817-824, following peer review and can also be viewed on the journal's website at ard.bmj.com. | | https://creativecommons.org/licenses/by-nc/3.0/ |
| Type: | article |
| URI: | http://hdl.handle.net/2115/62832 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 小池 隆夫
|
